Tumour markers in internal medicine: A low-cost test or an unnecessary expense? A retrospective study based on appropriateness

Internal and Emergency Medicine

Volumn 2, Issue 2, 2007, Pages 88-94

  Arioli, D ^a   Pipino, M ^a   Boldrini, E ^a   Amateis, E ^a   Cristani, A ^a   Ventura, P ^a   Romagnoli, E ^a   De Santis, M C ^a   Zeneroli, M L ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Clinical practice; Decision making process; Guidelines; Internal medicine; Positive predictive value; Tumour markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 34547225503     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-007-0028-8     Document Type: Article

References (39)

1. Hayes DF, Bast RC, Desch CE et al (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466
2. Smith RA, Cokkinides V, von Eschenbach AC et al (2002) American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 52:8-22
3. Smith RA, Mettlin CJ, Davis KJ, Eyre H (2000) American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 50:34-49
4. Schrohl AS, Holten-Andersen M, Sweep F et al (2003) Tumor markers: from laboratory to clinical utility. Mol Cell Proteomics 2:378-387
5. Durieux P, Ravaud P, Porcher R, Fulla Y, Manet CS, Chaussade S (2003) Long-term impact of a restrictive laboratory test ordering form on tumor marker prescriptions. Int J Technol Assess Health Care 19:106-113
6. - (1981) Carcinoembryonic antigen: its role as a marker in the management of cancer. Summary of an NIH consensus statement. Br Med J (Clin Res Ed) 282:373-375
7. - (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14:2843-2877
8. Duffy MJ, van Dalen A, Haglund C et al (2003) Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39:718-727
9. Bast RC Jr, Ravdin P, Hayes DF et al (2000) update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878
10. Cheung KL (2002) Editorial comment on 'serum markers in breast cancer management'. Eur J Cancer 38:1165-1166
11. Riker A, Libutti SK, Bartlett DL (1997) Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 6:157-169
12. - (2002) ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 100:1413-1416
13. Partridge EE, Barnes MN (1999) Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 49:297-320
14. Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151-1159
15. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
16. Ikeda Y, Oomori H, Koyanagi N et al (1995) Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer. Oncology 52:483-486
17. Ng WW, Tong KJ, Tam TN, Lee SD (1995) Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice. Zhonghua Yi Xue Za Zhi (Taipei) 55:438-446
18. Redaelli CA, Buchler MW, Schilling MK et al (1997) High coincidence of Mirizzi syndrome and gallbladder carcinoma. Surgery 121:58-63
19. Torok N, Gores GJ (2001) Cholangiocarcinoma. Semin Gastrointest Dis 12:125-132
20. Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M (2001) Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 22:318-322
21. Torzilli G, Makuuchi M, Ferrero A et al (2002) Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients. Hepatogastroenterology 49:740-745
22. Banfi G, Ardemagni A, Bravi S, Pacchioni M, Bonini P (1996) Are diabetic metabolic compensation and CA19.9 really correlated? Int J Biol Markers 11:207-210
23. Ogawa Y, Tanaka M, Inoue K et al (2002) A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 94:2344-2349
24. Diez M, Gomez A, Hernando F et al (1995) Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non small cell lung cancer. Int J Biol Markers 10:5-10
25. Salgia R, Harpole D, Herndon JE 2nd et al (2001) Role of serum tumor markers Ca 125 and Cea in non-small cell lung cancer. Anticancer Res 21:1241-1246
26. Whitmore SE, Anhalt GJ, Provost TT et al (1997) Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol 65:241-244
27. Amoura Z, Duhaut P, Huong DL et al (2005) Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 14:1279-1282
28. Rustin GJ, Quinn M, Thigpen T et al (2004) Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96:487-488
29. Sackett DL, Straus S, Richardson S, Rosenberg W, Haynes RB (2000) Evidence-based medicine: how to practice and teach EBM, 2nd edn. Churchill Livingstone, London
30. Field MJ (1992) Guidelines for clinical practice: from development to use. Institute of Medicine. National Academy Press, Washington, DC
31. Scandellari C (2005) La diagnosi clinica: Principi metodologici del procedimento decisionale. Masson, Milan
32. - (1979) The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 121:1193-1254
33. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E (1990) Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol 43:891-905
34. Woolf SH (1993) Practice guidelines: a new reality in medicine. III. Impact on patient care. Arch Intern Med 153:2646-2655
35. Naka T, Yorifuji S, Fujimura H, Takahashi M, Tarui S (1991) [A case of paraneoplastic neuropathy with necrotizing arteritis localized in the peripheral nervous system]. Rinsho Shinkeigaku 31:427-432
36. Mason WP, Dalmau J, Curtin JP, Posner JB (1997) Normalization of the tumor marker CA-125 after oophorectomy in a patient with paraneoplastic cerebellar degeneration without detectable cancer. Gynecol Oncol 65:173-176
37. Liu S, Tunkel R, Lachmann E, Nagler W (2000) Paraneoplastic cerebellar degeneration as the first evidence of cancer: a case report. Arch Phys Med Rehabil 81:834-836
38. Hwang SJ, Luo JC, Li CP et al (2004) Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 10:2472-2477
39. Monreal M, Lafoz E, Casals A et al (1991) Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer 67:541-545